Wuttipong Phumrattanaprapin1, Sujittra Chaiyadet2, Paul J Brindley3, Mark Pearson4, Michael J Smout4, Alex Loukas4, Thewarach Laha1. 1. Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. 2. Tropical Medicine Graduate Program, Academic Affairs, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. 3. Department of Microbiology, Immunology and Tropical Medicine, Research Center for Neglected Diseases of Poverty, School of Medicine and Health Sciences, George Washington University, Washington, District of Columbia, USA. 4. Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Queensland, Australia.
Abstract
BACKGROUND: The human liver fluke Opisthorchis viverrini is a food-borne trematode that causes hepatobiliary disease in humans throughout Southeast Asia. People become infected by consuming raw or undercooked fish containing metacercariae. Development of a vaccine to prevent or minimize pathology would decrease the risk of severe morbidity, including the development of bile duct cancer. METHODS: We produced an oral vaccine based on recombinant Bacillus subtilis spores expressing the large extracellular loop (LEL) of O. viverrini tetraspanin-2 (Ov-TSP-2), a protein that is abundant on the surface of O. viverrini secreted extracellular vesicles (EVs). Recombinant spores expressing Ov-TSP-2-LEL were orally administered to hamsters prior to challenge infection with O. viverrini metacercariae. RESULTS: Vaccinated hamsters generated serum IgG as well as bile IgG and IgA responses to Ov-TSP-2-LEL, and serum IgG from vaccinated hamsters blocked the uptake of fluke EVs by a human bile duct epithelial cell line. Vaccinated hamsters had 56% reductions in both adult flukes and fecal eggs compared to the control group. CONCLUSIONS: These findings indicate that oral vaccination of hamsters with recombinant B. subtilis spores expressing Ov-TSP-2-LEL is efficacious at reducing infection intensity and could form the basis of a vaccine for control of carcinogenic liver fluke infection in humans.
BACKGROUND: The human liver fluke Opisthorchis viverrini is a food-borne trematode that causes hepatobiliary disease in humans throughout Southeast Asia. People become infected by consuming raw or undercooked fish containing metacercariae. Development of a vaccine to prevent or minimize pathology would decrease the risk of severe morbidity, including the development of bile duct cancer. METHODS: We produced an oral vaccine based on recombinant Bacillus subtilis spores expressing the large extracellular loop (LEL) of O. viverrini tetraspanin-2 (Ov-TSP-2), a protein that is abundant on the surface of O. viverrini secreted extracellular vesicles (EVs). Recombinant spores expressing Ov-TSP-2-LEL were orally administered to hamsters prior to challenge infection with O. viverrini metacercariae. RESULTS: Vaccinated hamsters generated serum IgG as well as bile IgG and IgA responses to Ov-TSP-2-LEL, and serum IgG from vaccinated hamsters blocked the uptake of fluke EVs by a human bile duct epithelial cell line. Vaccinated hamsters had 56% reductions in both adult flukes and fecal eggs compared to the control group. CONCLUSIONS: These findings indicate that oral vaccination of hamsters with recombinant B. subtilis spores expressing Ov-TSP-2-LEL is efficacious at reducing infection intensity and could form the basis of a vaccine for control of carcinogenic liver fluke infection in humans.
Authors: R Isticato; G Cangiano; H T Tran; A Ciabattini; D Medaglini; M R Oggioni; M De Felice; G Pozzi; E Ricca Journal: J Bacteriol Date: 2001-11 Impact factor: 3.490
Authors: Mai H Tran; Mark S Pearson; Jeffrey M Bethony; Danielle J Smyth; Malcolm K Jones; Mary Duke; Tegan A Don; Donald P McManus; Rodrigo Correa-Oliveira; Alex Loukas Journal: Nat Med Date: 2006-06-18 Impact factor: 53.440
Authors: Jason Mulvenna; Luke Moertel; Malcolm K Jones; Sujeevi Nawaratna; Erica M Lovas; Geoffrey N Gobert; Michelle Colgrave; Alun Jones; Alex Loukas; Donald P McManus Journal: Int J Parasitol Date: 2009-10-22 Impact factor: 3.981
Authors: Sujittra Chaiyadet; Javier Sotillo; Michael Smout; Cinzia Cantacessi; Malcolm K Jones; Michael S Johnson; Lynne Turnbull; Cynthia B Whitchurch; Jeremy Potriquet; Marut Laohaviroj; Jason Mulvenna; Paul J Brindley; Jeffrey M Bethony; Thewarach Laha; Banchob Sripa; Alex Loukas Journal: J Infect Dis Date: 2015-05-17 Impact factor: 5.226
Authors: Patpicha Arunsan; Wannaporn Ittiprasert; Michael J Smout; Alex Loukas; Paul J Brindley; Thewarach Laha; Christina J Cochran; Victoria H Mann; Sujittra Chaiyadet; Shannon E Karinshak; Banchob Sripa; Neil David Young; Javier Sotillo Journal: Elife Date: 2019-01-15 Impact factor: 8.140
Authors: Wuttipong Phumrattanaprapin; Mark Pearson; Darren Pickering; Bemnet Tedla; Michael Smout; Sujittra Chaiyadet; Paul J Brindley; Alex Loukas; Thewarach Laha Journal: Vaccines (Basel) Date: 2021-07-05